Track and record of
success in oncology
In 1994 Farmitalia Carlo Erba was sold to the Swedish group Kabi-Pharmacia; it was in this period that the first aromatase inhibitor, Hexamestane, was discovered, developed and commercialized.
Recently Nerpharma has been focusing on the development of innovative technologies and new drug delivery systems and can boast important collaborations such as the one with the Swedish Xspray whose technology, implemented in Nerviano, was approved by AIFA in March 2020; with a Swiss Biotech company for the production of oncology products in dual chamber bags, a technology approved by EMA in September 2020 and finally the collaboration with a Specialty Pharma based in California – USA for automatic chemotherapy infusion systems.
The company history highlights the ability to combine well-established technical & scientific skills with innovative inspiration aimed at guaranteeing patients and partners the possibility of having the best drug in the pharmaceutical form that best suits the individual needs.